Disabling Cellular Recycling Gene Boosts Membrane Protein Yields for Drug Discovery

Researchers at the KTH Royal Institute of Technology, in collaboration with AstraZeneca, have increased the production of difficult-to-manufacture membrane proteins by disabling a cellular recycling pathway.

By knocking out the ULK1 gene, the team achieved yield increases of up to 100 percent in human cell lines used for pharmaceutical development.

Membrane proteins represent the targets for approximately 60 percent of all approved medicines, yet they remain notoriously difficult to produce in the quantities required for rigorous research and development. By targeting the autophagy pathway—the cell’s natural "clean-up crew"—researchers have identified a method to bypass traditional limitations in protein expression, as detailed in the journal Cell Systems.

  • Enhanced Efficiency: Scientists can now produce significantly higher amounts of proteins that were previously difficult to manufacture, potentially lowering the costs of drug discovery.
  • Targeting Autophagy: By disabling the ULK1 gene, which normally breaks down proteins, cells are repurposed to focus their energy on creating specific, medically relevant proteins.

The research team moved away from the conventional approach of boosting cellular production machinery. Instead, they focused on the ULK1 gene, which initiates autophagy. While autophagy is essential for maintaining cell health and clearing out damaged organelles, the researchers discovered that its removal did not negatively impact the viability of the human cell lines used in the study.

Disabling cells cleanu
Photo: financialgazette.co.uk

“We expected cells without working autophagy to struggle. Instead, they produced more, and they did best with exactly the proteins that are usually hardest to obtain,” said Johan Rockberg, professor of directed evolution at KTH, according to News-Medical.

The study utilized three model proteins—GIPR, GPR75, and P2X3—to test the effectiveness of the ULK1 knockout. The results demonstrated a direct correlation between the inhibition of the autophagy pathway and increased protein yield.

Alice Karlsson, a doctoral student in biotechnology at KTH, said that the team observed clear signs in the transcriptome—the complete set of RNA transcripts in the cell—confirming the downregulation of autophagy and subsequent improvements in protein expression.

“The most rewarding part was seeing the effect of knocking out ULK1 and that it led to clear signs in the transcriptome with downregulation of autophagy and downstream processes,” said Alice Karlsson, doctoral student in biotechnology at KTH.

“The biggest surprise was that it also translated into higher yields of our model proteins,” Karlsson said.

KTH Royal Institute of Technology, Sweden’s largest technical university, traces its origins to the Laboratorium Mechanicum founded in 1697 by Christopher Polhem. It was formally established as the Teknologiska institutet in 1827 and received its current name in 1877.

The university conducts research and education in engineering and technology across five schools with four campuses in and around Stockholm. In the 2025 QS World University Rankings, KTH ranked 74th globally, the highest position among universities in the Nordic countries.

Target Protein Yield Increase (%)
GIPR 30%
GPR75 80%
P2X3 100%

The project was a collaborative effort between KTH Royal Institute of Technology and AstraZeneca. Financial support for the research was provided by the Knut and Alice Wallenberg Foundation, AstraZeneca, and the Swedish innovation agency Vinnova, through the GeneNova, AAVNova, CellNova, and AdBIOPRO initiatives. The study lists 15 authors, including Alice Karlsson, Melanie Dannemeyer, and Jenny Gunnarsson.

Photo of author

Health Desk

Health Desk at Archyde.

Microsoft Releases RDMA Over USB4 Preview, Cuts Latency 4x, Tests 120B Model